(Irvine, CA)– Next Pharmaceuticals, Inc. is launching its new ingredient Seditol™ to help the 70 million Americans who can’t sleep due to an overactive central nervous system. A recent study at the Sleep Research and Treatment Center, Department of Psychiatry, Pennsylvania State University College of Medicine has demonstrated that the leading cause of sleeplessness in otherwise healthy adults is an overactive central nervous system with associated elevation of stress hormones such as cortisol.¹ Seditol™ was developed to uniquely address the need to improve nighttime sleep by helping to normalize nighttime stress hormone levels while providing a feeling of relaxation and less worry.

Seditol™ is a blend of a patented extract of Magnolia officinalis (U.S. Patent No. US 6,582,735) and a proprietary extract of Ziziphus spinosa. In an August 2004 50-subject trial conducted by Target Research Group, Inc., Nanuet, NY, the benefits of Seditol™ were clearly demonstrated. The subjects that took Seditol™ as directed reported the following results:
• 83% Said Seditol™ helps insure a sound night’s sleep
• 87% Said Seditol™ helps you relax
• 87% Said Seditol™ reduces fatigue due to lack of sleep
• 87% said Seditol™ allows you to wake up feeling refreshed

“The scientists at Penn State concluded in their study that the therapeutic goal in sleeplessness should be to decrease the level of physical and emotional arousal, and not just improve nighttime sleep” says Next Pharmaceuticals’ CEO Bob Garrison. “This is exactly what Seditol™ has been developed to do. We have five human studies and numerous pharmacological studies that have shown our patented botanical extract in Seditol™ hits the desired CNS receptors and produces the improved quality of sleep stressed people so urgently need.”

Seditol™ is available to manufacturers of dietary supplements as a stand alone product, or as an ingredient in combination formulas. Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients to dietary supplement, food, and beverage companies focused on products for healthy living. For more information on Seditol™ or Next’s other ingredients, visit www.nextpharmaceuticals.com.

^1. Vgontzas A., Bixler E. et al: Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.  J Clin Endrocinol Metab 86: 3787-3794,2001.

###

Source:
Next Pharmaceuticals, Inc.

Contact:
Dayna Bird
Telephone: 949.450.0203 ext. 15